Center for Primary Health Care Research, Lund University/Region Skåne, Malmö, Sweden.
Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Br J Cancer. 2021 Jan;124(2):506-512. doi: 10.1038/s41416-020-01108-9. Epub 2020 Oct 7.
Expensive cancer treatment calls for alternative ways such as drug repurposing to develop effective drugs. The aim of this study was to analyse the effect of post-diagnostic use of cholera vaccine on survival outcome in breast cancer patients.
Cancer diagnosis and cholera vaccination were obtained by linkage of several Swedish national registries. One vaccinated patient was matched with maximum two unvaccinated individuals based on demographic, clinical and socioeconomic factors. We performed proportional Cox regression model to analyse the differences in overall and disease-specific survivals between the matched patients.
In total, 617 patients received cholera vaccine after breast cancer diagnosis. The median (interquartile range) time from diagnosis to vaccination was 30 (15-51) months and from vaccination to the end of follow-up it was 62 (47-85) months. Among them, 603 patients were matched with 1194 unvaccinated patients. Vaccinated patients showed favourable overall survival (hazard ratio (HR): 0.54, 95% confidence interval (CI): 0.37-0.79) and disease-specific survival (HR: 0.53, 95% CI: 0.33-0.84), compared to their unvaccinated counterpart. The results were still significant in multiple sensitivity analyses.
Post-diagnostic use of cholera vaccine is associated with a favourable survival rate in breast cancer patients; this provides evidence for repurposing it against breast cancer.
昂贵的癌症治疗需要寻找替代方法，例如药物再利用，以开发有效的药物。本研究旨在分析诊断后使用霍乱疫苗对乳腺癌患者生存结果的影响。
通过链接几个瑞典国家登记处获得癌症诊断和霍乱疫苗接种情况。根据人口统计学、临床和社会经济因素，为每位接种疫苗的患者匹配最多两名未接种疫苗的个体。我们采用比例 Cox 回归模型分析匹配患者之间总生存率和疾病特异性生存率的差异。
共有 617 例乳腺癌患者在诊断后接受了霍乱疫苗接种。从诊断到接种疫苗的中位数（四分位间距）时间为 30（15-51）个月，从接种疫苗到随访结束的中位数时间为 62（47-85）个月。其中，603 例患者与 1194 例未接种疫苗的患者进行了匹配。与未接种疫苗的患者相比，接种疫苗的患者总生存率（风险比（HR）：0.54，95%置信区间（CI）：0.37-0.79）和疾病特异性生存率（HR：0.53，95%CI：0.33-0.84）均有改善。多项敏感性分析结果仍具有统计学意义。
诊断后使用霍乱疫苗与乳腺癌患者的生存率提高相关；这为将其重新用于治疗乳腺癌提供了证据。
